首页> 外文期刊>Statistics in medicine >Sample size determination in clinical trials with multiple co-primary binary endpoints.
【24h】

Sample size determination in clinical trials with multiple co-primary binary endpoints.

机译:在具有多个共同主要二元终点的临床试验中确定样本量。

获取原文
获取原文并翻译 | 示例
           

摘要

Clinical trials often employ two or more primary efficacy endpoints. One of the major problems in such trials is how to determine a sample size suitable for multiple co-primary correlated endpoints. We provide fundamental formulae for the calculation of power and sample size in order to achieve statistical significance for all the multiple primary endpoints given as binary variables. On the basis of three association measures among primary endpoints, we discuss five methods of power and sample size calculation: the asymptotic normal method with and without continuity correction, the arcsine method with and without continuity correction, and Fisher's exact method. For all five methods, the achieved sample size decreases as the value of association measure increases when the effect sizes among endpoints are approximately equal. In particular, a high positive association has a greater effect on the decrease in the sample size. On the other hand, such a relationship is not very strong when the effect sizes are different.
机译:临床试验通常采用两个或多个主要功效终点。这种试验中的主要问题之一是如何确定适合多个共同主要相关终点的样本量。我们提供了用于计算功效和样本数量的基本公式,以实现对以二进制变量形式给出的所有多个主要终点的统计意义。在主要端点之间的三种关联度量的基础上,我们讨论了功效和样本大小计算的五种方法:带有和不带有连续性校正的渐近法线法,带有和不带有连续性校正的反正弦法以及费舍尔精确法。对于所有五种方法,当端点之间的效果大小近似相等时,随着关联度量值的增加,实现的样本大小将减小。尤其是,高度正相关对减少样本量具有更大的影响。另一方面,当效果大小不同时,这种关系不是很牢固。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号